SI113, a specific inhibitor of the Sgk1 kinase activity that counteracts cancer cell proliferation

Lucia D'Antona, Rosario Amato, Cristina Talarico, Francesco Ortuso, Miranda Menniti, Vincenzo Dattilo, Rodolfo Iuliano, Francesco Gigliotti, Anna Artese, Giosuè Costa, Silvia Schenone, Francesca Musumeci, Claudia Abbruzzese, Lorenzo Botta, Francesco Trapasso, Stefano Alcaro, Marco G. Paggi, Nicola Perrotti

Research output: Contribution to journalArticle

Abstract

Background/Aims: Published observations on serum and glucocorticoid regulated kinase 1 (Sgk1) knockout murine models and Sgk1-specific RNA silencing in the RKO human colon carcinoma cell line point to this kinase as a central player in colon carcinogenesis and in resistance to taxanes. Methods: By in vitro kinase activity inhibition assays, cell cycle and viability analysis in human cancer model systems, we describe the biologic effects of a recently identified kinase inhibitor, SI113, characterized by a substituted pyrazolo[3,4-d]pyrimidine scaffold, that shows specificity for Sgk1. Results: SI113 was able to inhibit in vitro cell growth in cancer cells derived from tumors with different origins. In RKO cells, this kinase inhibitor blocked insulin-dependent phosphorylation of the Sgk1 substrate Mdm2, the main regulator of p53 protein stability, and induced necrosis and apoptosis when used as a single agent. Finally, SI113 potentiated the effects of paclitaxel on cell viability. Conclusion: Since SI113 appears to be effective in inducing cell death in RKO cells, potentiating paclitaxel sensitivity, we believe that this new molecule could be efficiently employed, alone or in combination with paclitaxel, in colon cancer chemotherapy.

Original languageEnglish
Pages (from-to)2006-2018
Number of pages13
JournalCellular Physiology and Biochemistry
Volume35
Issue number5
DOIs
Publication statusPublished - May 6 2015

Fingerprint

Phosphotransferases
Paclitaxel
Cell Proliferation
pyrazolo(3,4-d)pyrimidine
Neoplasms
Cell Survival
Colon
Taxoids
Protein Stability
RNA Interference
Colonic Neoplasms
Cell Cycle
Carcinogenesis
Cell Death
Necrosis
Phosphorylation
Insulin
Apoptosis
Carcinoma
Drug Therapy

Keywords

  • Apoptosis
  • Cancer
  • Kinase inhibitor
  • Necrosis
  • SGK1
  • Small molecule

ASJC Scopus subject areas

  • Physiology
  • Medicine(all)

Cite this

D'Antona, L., Amato, R., Talarico, C., Ortuso, F., Menniti, M., Dattilo, V., ... Perrotti, N. (2015). SI113, a specific inhibitor of the Sgk1 kinase activity that counteracts cancer cell proliferation. Cellular Physiology and Biochemistry, 35(5), 2006-2018. https://doi.org/10.1159/000374008

SI113, a specific inhibitor of the Sgk1 kinase activity that counteracts cancer cell proliferation. / D'Antona, Lucia; Amato, Rosario; Talarico, Cristina; Ortuso, Francesco; Menniti, Miranda; Dattilo, Vincenzo; Iuliano, Rodolfo; Gigliotti, Francesco; Artese, Anna; Costa, Giosuè; Schenone, Silvia; Musumeci, Francesca; Abbruzzese, Claudia; Botta, Lorenzo; Trapasso, Francesco; Alcaro, Stefano; Paggi, Marco G.; Perrotti, Nicola.

In: Cellular Physiology and Biochemistry, Vol. 35, No. 5, 06.05.2015, p. 2006-2018.

Research output: Contribution to journalArticle

D'Antona, L, Amato, R, Talarico, C, Ortuso, F, Menniti, M, Dattilo, V, Iuliano, R, Gigliotti, F, Artese, A, Costa, G, Schenone, S, Musumeci, F, Abbruzzese, C, Botta, L, Trapasso, F, Alcaro, S, Paggi, MG & Perrotti, N 2015, 'SI113, a specific inhibitor of the Sgk1 kinase activity that counteracts cancer cell proliferation', Cellular Physiology and Biochemistry, vol. 35, no. 5, pp. 2006-2018. https://doi.org/10.1159/000374008
D'Antona, Lucia ; Amato, Rosario ; Talarico, Cristina ; Ortuso, Francesco ; Menniti, Miranda ; Dattilo, Vincenzo ; Iuliano, Rodolfo ; Gigliotti, Francesco ; Artese, Anna ; Costa, Giosuè ; Schenone, Silvia ; Musumeci, Francesca ; Abbruzzese, Claudia ; Botta, Lorenzo ; Trapasso, Francesco ; Alcaro, Stefano ; Paggi, Marco G. ; Perrotti, Nicola. / SI113, a specific inhibitor of the Sgk1 kinase activity that counteracts cancer cell proliferation. In: Cellular Physiology and Biochemistry. 2015 ; Vol. 35, No. 5. pp. 2006-2018.
@article{dfc40354829d4d419eae814077f5fda5,
title = "SI113, a specific inhibitor of the Sgk1 kinase activity that counteracts cancer cell proliferation",
abstract = "Background/Aims: Published observations on serum and glucocorticoid regulated kinase 1 (Sgk1) knockout murine models and Sgk1-specific RNA silencing in the RKO human colon carcinoma cell line point to this kinase as a central player in colon carcinogenesis and in resistance to taxanes. Methods: By in vitro kinase activity inhibition assays, cell cycle and viability analysis in human cancer model systems, we describe the biologic effects of a recently identified kinase inhibitor, SI113, characterized by a substituted pyrazolo[3,4-d]pyrimidine scaffold, that shows specificity for Sgk1. Results: SI113 was able to inhibit in vitro cell growth in cancer cells derived from tumors with different origins. In RKO cells, this kinase inhibitor blocked insulin-dependent phosphorylation of the Sgk1 substrate Mdm2, the main regulator of p53 protein stability, and induced necrosis and apoptosis when used as a single agent. Finally, SI113 potentiated the effects of paclitaxel on cell viability. Conclusion: Since SI113 appears to be effective in inducing cell death in RKO cells, potentiating paclitaxel sensitivity, we believe that this new molecule could be efficiently employed, alone or in combination with paclitaxel, in colon cancer chemotherapy.",
keywords = "Apoptosis, Cancer, Kinase inhibitor, Necrosis, SGK1, Small molecule",
author = "Lucia D'Antona and Rosario Amato and Cristina Talarico and Francesco Ortuso and Miranda Menniti and Vincenzo Dattilo and Rodolfo Iuliano and Francesco Gigliotti and Anna Artese and Giosu{\`e} Costa and Silvia Schenone and Francesca Musumeci and Claudia Abbruzzese and Lorenzo Botta and Francesco Trapasso and Stefano Alcaro and Paggi, {Marco G.} and Nicola Perrotti",
year = "2015",
month = "5",
day = "6",
doi = "10.1159/000374008",
language = "English",
volume = "35",
pages = "2006--2018",
journal = "Cellular Physiology and Biochemistry",
issn = "1015-8987",
publisher = "S. Karger AG",
number = "5",

}

TY - JOUR

T1 - SI113, a specific inhibitor of the Sgk1 kinase activity that counteracts cancer cell proliferation

AU - D'Antona, Lucia

AU - Amato, Rosario

AU - Talarico, Cristina

AU - Ortuso, Francesco

AU - Menniti, Miranda

AU - Dattilo, Vincenzo

AU - Iuliano, Rodolfo

AU - Gigliotti, Francesco

AU - Artese, Anna

AU - Costa, Giosuè

AU - Schenone, Silvia

AU - Musumeci, Francesca

AU - Abbruzzese, Claudia

AU - Botta, Lorenzo

AU - Trapasso, Francesco

AU - Alcaro, Stefano

AU - Paggi, Marco G.

AU - Perrotti, Nicola

PY - 2015/5/6

Y1 - 2015/5/6

N2 - Background/Aims: Published observations on serum and glucocorticoid regulated kinase 1 (Sgk1) knockout murine models and Sgk1-specific RNA silencing in the RKO human colon carcinoma cell line point to this kinase as a central player in colon carcinogenesis and in resistance to taxanes. Methods: By in vitro kinase activity inhibition assays, cell cycle and viability analysis in human cancer model systems, we describe the biologic effects of a recently identified kinase inhibitor, SI113, characterized by a substituted pyrazolo[3,4-d]pyrimidine scaffold, that shows specificity for Sgk1. Results: SI113 was able to inhibit in vitro cell growth in cancer cells derived from tumors with different origins. In RKO cells, this kinase inhibitor blocked insulin-dependent phosphorylation of the Sgk1 substrate Mdm2, the main regulator of p53 protein stability, and induced necrosis and apoptosis when used as a single agent. Finally, SI113 potentiated the effects of paclitaxel on cell viability. Conclusion: Since SI113 appears to be effective in inducing cell death in RKO cells, potentiating paclitaxel sensitivity, we believe that this new molecule could be efficiently employed, alone or in combination with paclitaxel, in colon cancer chemotherapy.

AB - Background/Aims: Published observations on serum and glucocorticoid regulated kinase 1 (Sgk1) knockout murine models and Sgk1-specific RNA silencing in the RKO human colon carcinoma cell line point to this kinase as a central player in colon carcinogenesis and in resistance to taxanes. Methods: By in vitro kinase activity inhibition assays, cell cycle and viability analysis in human cancer model systems, we describe the biologic effects of a recently identified kinase inhibitor, SI113, characterized by a substituted pyrazolo[3,4-d]pyrimidine scaffold, that shows specificity for Sgk1. Results: SI113 was able to inhibit in vitro cell growth in cancer cells derived from tumors with different origins. In RKO cells, this kinase inhibitor blocked insulin-dependent phosphorylation of the Sgk1 substrate Mdm2, the main regulator of p53 protein stability, and induced necrosis and apoptosis when used as a single agent. Finally, SI113 potentiated the effects of paclitaxel on cell viability. Conclusion: Since SI113 appears to be effective in inducing cell death in RKO cells, potentiating paclitaxel sensitivity, we believe that this new molecule could be efficiently employed, alone or in combination with paclitaxel, in colon cancer chemotherapy.

KW - Apoptosis

KW - Cancer

KW - Kinase inhibitor

KW - Necrosis

KW - SGK1

KW - Small molecule

UR - http://www.scopus.com/inward/record.url?scp=84927945625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927945625&partnerID=8YFLogxK

U2 - 10.1159/000374008

DO - 10.1159/000374008

M3 - Article

C2 - 25871776

AN - SCOPUS:84927945625

VL - 35

SP - 2006

EP - 2018

JO - Cellular Physiology and Biochemistry

JF - Cellular Physiology and Biochemistry

SN - 1015-8987

IS - 5

ER -